| answer text |
<p>The Department is proud to invest £1.3 billion per year in health research through
the National Institute for Health and Care Research (NIHR). NIHR research expenditure
for all cancers was over £121.8 million for 2022/23, with more spent on cancer than
any other disease group. In 2018, the Government announced £75 million towards clinical
trials for prostate cancer, with a focus on improving early diagnosis, survival rates,
and exploring options for different treatments for men affected by the disease.</p><p>
</p><p>Since April 2019, the NIHR has awarded £79.1 million across 49 prostate cancer
research programmes. Research includes randomised controlled trials of different treatments
for prostate cancer, a randomised controlled trial of different methods of biopsy
for suspected prostate cancer, and survivors' rehabilitation evaluation after cancer.</p><p>
</p><p>On 19 November 2023, the Government and Prostate Cancer UK announced a £42
million screening trial to find ways of detecting the country’s most common male cancer
earlier. Prostate Cancer UK is leading the development of the trial, with the Government
contributing £16 million through the Department. Additionally, the NIHR supported
over 100 commercial and non-commercial clinical research studies in 2023/24, through
the NIHR Research Delivery Network.</p>
|
|
